Recent rumors hinted that Teva could continue its expansion into the world of branded drugs. Israeli business newspaper Calcalist reported that Teva was considering an acquisition of Amarin ( AMRN 4.06% ). While Amarin's decision to move forward with hiring its own sales force might have tempered expectations for a near-term deal with any third party, CEO Joe Zakrzewski didn't rule out the possibility of future partnerships or mergers.